Chung Wu Investment Group LLC Takes $173,000 Position in Insmed, Inc. $INSM

Key Points

• Chung Wu Investment Group LLC acquired a new position in Insmed, Inc., purchasing 1,720 shares valued at approximately $173,000 during the second quarter, indicating institutional interest in the biopharmaceutical company.
• Insider trading activity shows that CFO Sara Bonstein and COO Roger Adsett sold significant portions of their stakes, with Bonstein selling 58,400 shares for about $6 million and Adsett selling 25,000 shares for approximately $3.2 million.
• Analysts have raised price targets for Insmed, with Royal Bank of Canada increasing their target from $108 to $120, reflecting positive sentiment in the stock's future performance.

Chung Wu Investment Group LLC acquired a new position in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,720 shares of the biopharmaceutical company's stock, valued at approximately $173,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in INSM. Wealth Enhancement Advisory Services LLC grew its stake in Insmed by 10.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 3,231 shares of the biopharmaceutical company's stock valued at $223,000 after acquiring an additional 307 shares during the period. NBC Securities Inc. bought a new position in shares of Insmed in the 1st quarter worth $49,000. Park Avenue Securities LLC grew its position in Insmed by 38.7% in the 1st quarter. Park Avenue Securities LLC now owns 11,036 shares of the biopharmaceutical company's stock valued at $842,000 after purchasing an additional 3,081 shares during the period. Harbor Capital Advisors Inc. grew its position in Insmed by 22.2% in the 1st quarter. Harbor Capital Advisors Inc. now owns 72,816 shares of the biopharmaceutical company's stock valued at $5,555,000 after purchasing an additional 13,216 shares during the period. Finally, GAMMA Investing LLC increased its stake in Insmed by 62.0% during the 1st quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company's stock valued at $77,000 after purchasing an additional 386 shares in the last quarter.

Insiders Place Their Bets

In other Insmed news, CFO Sara Bonstein sold 58,400 shares of the firm's stock in a transaction dated Monday, July 21st. The stock was sold at an average price of $102.67, for a total value of $5,995,928.00. Following the sale, the chief financial officer owned 73,505 shares of the company's stock, valued at $7,546,758.35. This trade represents a 44.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Roger Adsett sold 25,000 shares of Insmed stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total value of $3,189,500.00. Following the sale, the chief operating officer owned 105,637 shares of the company's stock, valued at approximately $13,477,168.46. This trade represents a 19.14% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 219,568 shares of company stock worth $28,305,070. 3.00% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have weighed in on INSM shares. Royal Bank Of Canada raised their price objective on shares of Insmed from $108.00 to $120.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. TD Cowen raised their price target on shares of Insmed from $154.00 to $193.00 and gave the company a "buy" rating in a research report on Thursday. The Goldman Sachs Group lifted their price target on Insmed from $121.00 to $196.00 and gave the company a "buy" rating in a research note on Friday. William Blair started coverage on Insmed in a research note on Wednesday, August 20th. They issued an "outperform" rating for the company. Finally, Truist Financial lifted their target price on Insmed from $126.00 to $139.00 and gave the company a "buy" rating in a research report on Thursday, August 14th. Nineteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Insmed presently has a consensus rating of "Moderate Buy" and a consensus price target of $149.06.

Insmed Stock Performance

NASDAQ INSM opened at $157.16 on Monday. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $158.19. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The stock has a market capitalization of $33.22 billion, a PE ratio of -27.52 and a beta of 1.03. The company's 50 day simple moving average is $132.46 and its two-hundred day simple moving average is $99.25.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The firm had revenue of $107.42 million for the quarter, compared to analysts' expectations of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm's revenue for the quarter was up 18.9% on a year-over-year basis. During the same quarter last year, the firm earned ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. Analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.